Can Amikacin Replace Streptomycin for Pulmonary TB Treatment?
Yes, amikacin can be used instead of streptomycin to treat pulmonary tuberculosis when an injectable aminoglycoside is indicated, with current guidelines suggesting amikacin or streptomycin interchangeably when susceptibility is confirmed, though streptomycin may offer slightly better outcomes in drug-resistant TB. 1
Guideline Recommendations for Drug-Susceptible TB
For drug-susceptible pulmonary TB, injectable aminoglycosides are not routinely recommended in modern treatment regimens. 2 The standard first-line regimen consists of isoniazid, rifampin, pyrazinamide, and ethambutol, without the need for injectable agents. 3
However, when a fourth drug is needed (such as when INH or rifampin resistance is suspected), streptomycin is listed as an option alongside ethambutol, but injectable agents are generally avoided in favor of oral alternatives in contemporary practice. 3
Guideline Recommendations for Drug-Resistant TB (MDR/RR-TB)
Current Injectable Agent Hierarchy
For MDR-TB requiring an injectable agent, guidelines conditionally recommend amikacin or streptomycin when susceptibility is demonstrated and adequate monitoring for adverse reactions is ensured. 1
Key guideline statements:
- Amikacin and streptomycin are suggested for inclusion when susceptibility is confirmed (conditional recommendation, very low certainty of evidence). 1
- If amikacin is not available, streptomycin may replace amikacin under the same conditions. 1
- Kanamycin and capreomycin are NOT recommended for MDR-TB treatment. 1
Comparative Effectiveness Evidence
Recent high-quality research demonstrates streptomycin may have a slight advantage over amikacin in MDR-TB treatment outcomes:
A 2021 individual patient data meta-analysis of 12,030 patients from 25 countries found:
- Compared to kanamycin, amikacin was associated with 6 more cures per 100 patients (95% CI, 4-8). 4
- Streptomycin was associated with 7 more cures per 100 patients (95% CI, 5-8) and 5 fewer deaths per 100 patients (95% CI, 4-7) compared to kanamycin. 4
- Both amikacin and streptomycin significantly outperformed kanamycin and capreomycin, which showed no benefit over regimens without injectable drugs. 4
Practical Considerations for Drug Selection
When to Choose Amikacin Over Streptomycin
Amikacin may be preferred in the following situations:
- Greater availability: Amikacin is more readily available in many settings as it treats multiple types of infections. 1
- Easier therapeutic drug monitoring: Serum drug concentration measurements are more readily available for amikacin. 1
- Less vestibular toxicity: Some experts prefer amikacin due to perceived differences in severity of vestibular toxicity compared to streptomycin. 1
- Cross-resistance patterns: Most streptomycin-resistant strains remain susceptible to amikacin (though there is complete cross-resistance between amikacin and kanamycin). 1
When to Choose Streptomycin Over Amikacin
Streptomycin may be preferred when:
- Slightly better efficacy data: Recent meta-analysis suggests marginally superior outcomes with streptomycin in MDR-TB. 4
- Specific resistance patterns: In cases of high-level amikacin resistance (rrs 1400 mutation) with low-level streptomycin resistance (gidB mutation), streptomycin may still be effective. 5
- Less nephrotoxicity: Amikacin and kanamycin may be more nephrotoxic than streptomycin. 1
Dosing and Administration
Amikacin Dosing
- Adults: 15 mg/kg/day (maximum 1.0 g/day) intramuscular or intravenous, usually as a single daily dose initially, then reducing to 2-3 times weekly after first 2-4 months or after culture conversion. 1
- Patients >59 years: Reduce to 10 mg/kg/day (750 mg maximum). 1
- Alternative low-dose approach: 8-10 mg/kg with therapeutic drug monitoring has shown efficacy with lower toxicity rates (12.2% hearing loss vs. 24% with standard dosing). 6
Streptomycin Dosing
- Adults: 15 mg/kg/day (maximum 1 g/day) intramuscular, or 25-30 mg/kg 2-3 times weekly (maximum 1.5 g). 1
- Patients >59 years: Reduce to 10 mg/kg/day (750 mg maximum). 1
Duration of Injectable Therapy
For MDR-TB regimens containing amikacin or streptomycin, an intensive phase of 6-7 months is suggested, with duration modified according to patient response. 1
Toxicity Monitoring Requirements
Ototoxicity
- Baseline audiogram, vestibular testing, and Romberg testing required. 1
- Monthly assessments of auditory and vestibular symptoms. 1
- Amikacin causes more deafness (24% high-frequency hearing loss in one report), while streptomycin causes more vestibular dysfunction. 1
- Ototoxicity is usually irreversible; discontinue immediately if symptoms develop (unsteady gait, tinnitus, diminished hearing). 1
Nephrotoxicity
- Baseline serum creatinine measurement required. 1
- Monthly renal function monitoring. 1
- Amikacin may be more nephrotoxic than streptomycin (8.7% renal impairment with amikacin). 1
- Dose adjustment essential in renal insufficiency: Reduce frequency to 2-3 times weekly but maintain mg/kg dose (12-15 mg/kg per dose) to preserve concentration-dependent bactericidal effect. 1
Critical Contraindications
Both amikacin and streptomycin are contraindicated in pregnancy due to risk of fetal nephrotoxicity and congenital hearing loss. 1
Common Pitfalls to Avoid
Do not use kanamycin or capreomycin instead: These agents are specifically recommended against in current guidelines and show inferior outcomes. 1, 4
Do not assume cross-resistance: While amikacin and kanamycin have complete cross-resistance, most streptomycin-resistant strains remain susceptible to amikacin. 1
Do not underdose in renal insufficiency: Maintain the mg/kg dose but reduce frequency to preserve bactericidal activity. 1
Do not skip therapeutic drug monitoring: Especially important for amikacin to avoid toxicity while ensuring adequate exposure. 1
Do not use as monotherapy or in inadequate regimens: Injectable agents must be part of a complete MDR-TB regimen with at least 5 effective drugs to prevent resistance emergence. 1